BCR and diffuse large B-cell lymphoma: For example, chronically-active BCR signaling in DLBCL might be inhibited with MALT1 paracaspase inhibitors [221,222] or with various kinase inhibitors such as ibrutinib or acalabrutinib (BTK inhibitors), which have shown promising clinical activities [223,224] and a potential to be efficiently combined with a variety of other agents to kill DLBCL cells [225].